|

Armored and GPC3-targeted autologous CAR T-cell Clinical Trials

1 actively recruiting trial

Also known as: C-CAR031

Pipeline

Phase 1/2: 1

Top Sponsors

  • Shanghai AbelZeta Ltd.1

Indications

  • Liver Disease1
  • Liver Cancer1
  • Hepatocellular Carcinoma1
  • Cancer1

Other1 trial

A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.